Immediate Impact
1 from Science/Nature 24 standout
Citing Papers
Bispecific antibodies: advancing precision oncology
2024 Standout
Multiple myeloma
2024 Standout
Works of Iryna Kryachok being referenced
Weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in patients with multiple myeloma (MM) after one to three prior therapies: Initial results of the phase III BOSTON study.
2020
Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia
2016
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Iryna Kryachok | 125 | 121 | 69 | 19 | 190 | |
| Jean Cheung | 102 | 92 | 39 | 15 | 196 | |
| Giorgia Chiodin | 150 | 79 | 66 | 14 | 197 | |
| Rocío Corral | 68 | 89 | 51 | 14 | 215 | |
| Marina Motta | 142 | 86 | 124 | 25 | 257 | |
| Claudia Mannu | 66 | 147 | 50 | 19 | 206 | |
| Fernando Solano | 98 | 118 | 59 | 16 | 259 | |
| Veronika Navrkalová | 119 | 95 | 59 | 17 | 212 | |
| H. Yesid Estupiñán | 193 | 130 | 84 | 18 | 291 | |
| Elena Ribakovsky | 51 | 76 | 50 | 16 | 204 | |
| A Dattilo | 209 | 178 | 139 | 15 | 293 |
All Works
Loading papers...